Louis Garguilo

ARTICLES BY LOUIS

  • GSK And Others Panning For “New Gold” In Blockchain River
    GSK And Others Panning For “New Gold” In Blockchain River

    “We're keen to get complete access, and full visibility, to our supply chain. This will in fact give us that desired end-to-end supply-chain transparency. It will improve the quality of so many of our decisions,” says Barry Moore, Head of Clinical Supply Chain Solutions for GSK, and Chairman of the Clinical Supply Blockchain Working Group (CSBWG)

  • Message To Senator Warren From CDMOs: Rethink Education
    Message To Senator Warren From CDMOs: Rethink Education

    It’s been a season of discontent over political plans for drug pricing, health care, and the biopharma industry. However, a CEO of a CDMO isn’t thinking particularly about pharma- and healthcare-related proposals. It’s education that’s on his mind — and finding skilled workers locally.

  • Farm To Pharma: Outsourcing Lessons From Back Home
    Farm To Pharma: Outsourcing Lessons From Back Home

    Growing up on a farm in Idaho, Marty Hughes of Cidara Therapeutics learned this about quality: If you can afford old equipment, you can afford new equipment. Here’s what he means, and some other of his down-home aphorisms to improve your outsourcing activities.

  • Congressional Testimony: Stop Targeting U.S.-Based API Manufacturers
    Congressional Testimony: Stop Targeting U.S.-Based API Manufacturers

    A representative for U.S.-based CDMOs recently testified before Congress regarding the fact 80% of our API is manufactured overseas. If you ask me, they picked the right guy to hear from. Here’s some “supplemental testimony” you’ll want to hear from Edward Price, President & CEO, SEQENS N.A.

  • Women In Our Workforce: A Biogen Millennial Manages CMOs
    Women In Our Workforce: A Biogen Millennial Manages CMOs

    Tara Caiano, Virtual Plant Manager, Biogen is a young-woman professional. We featured her a few weeks ago, just after she had relocated from Biogen’s Boston location to manage an external supply-chain partner in Switzerland. She also spoke to me about some of her personal experiences. 

  • Manufacturing In The U.S.: “I Cried When I Saw The Demise”
    Manufacturing In The U.S.: “I Cried When I Saw The Demise”

    Returning manufacturing to the U.S. from overseas is a personal crusade for Harry Moser. He has remedial prescriptions for accomplishing this, and some surprising thoughts on the U.S. President. "If we let China continue to grow as fast as they have, we're toast,” he says. But much of our problem is self-inflicted.

  • Biogen’s “Virtual” Plant Manager Goes To Switzerland
    Biogen’s “Virtual” Plant Manager Goes To Switzerland

    Tara Caiano of Biogen packed up her belongings from her Boston-area homestead to resettle in Switzerland. This “virtual plant manager” was turning the virtual into the physical, you might say, a key concept and role within Biogen’s evolving supply-chain management strategy.

  • Do The Math: “Reshoring” Adds Up For Biopharma Manufacturing
    Do The Math: “Reshoring” Adds Up For Biopharma Manufacturing

    “Our mission is to bring back five million manufacturing jobs. That would balance the goods trade deficit in the U.S.,” says Harry Moser, founder of the Reshoring Initiative. “That deficit is about $800 billion per year. To make that amount of product would take about five million people — a 40% increase in US manufacturing.” Pharma, says Moser, should play a role. 

  • Outsourcing Equilibriums And Imbalances
    Outsourcing Equilibriums And Imbalances

    When it comes to outsourcing drug development and manufacturing, while some areas may be reaching a "saturation point" of sorts – a point where a higher percentage of outsourcing can or will not be attained – other areas are in need of a vital ramp up just to keep up. 

  • Biopharma Supply Chains At Industry 4.0
    Biopharma Supply Chains At Industry 4.0

    Have we moved the needle closer to “Biopharma 4.0,” and improved supply chains? Here’s what industry veterans were thinking the beginning of the year. One thing is certain: Pharma and Biotech have different ideas on what happens next. 

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.